U.S. markets close in 4 hours 29 minutes
  • S&P 500

    4,164.59
    -20.88 (-0.50%)
     
  • Dow 30

    34,055.40
    -145.27 (-0.42%)
     
  • Nasdaq

    13,904.06
    -148.29 (-1.06%)
     
  • Russell 2000

    2,222.18
    -40.49 (-1.79%)
     
  • Crude Oil

    63.07
    -0.06 (-0.10%)
     
  • Gold

    1,775.60
    -4.60 (-0.26%)
     
  • Silver

    25.90
    -0.20 (-0.79%)
     
  • EUR/USD

    1.2034
    +0.0053 (+0.45%)
     
  • 10-Yr Bond

    1.5890
    +0.0160 (+1.02%)
     
  • GBP/USD

    1.3988
    +0.0148 (+1.07%)
     
  • USD/JPY

    108.0730
    -0.7100 (-0.65%)
     
  • BTC-USD

    55,379.20
    -278.74 (-0.50%)
     
  • CMC Crypto 200

    1,247.84
    -51.12 (-3.94%)
     
  • FTSE 100

    6,988.76
    -30.77 (-0.44%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Rubius Therapeutics to Announce Third Quarter 2020 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
Rubius Therapeutics
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced plans to report third quarter 2020 financial results on Monday, November 9, 2020, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics’ manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
lori.melancon@rubiustx.com

Media:
Marissa Hanify
Director, Corporate Communications
marissa.hanify@rubiustx.com

Dan Budwick
1AB
+1 (973) 271-6085
dan@1abmedia.com